# Black Diamond Therapeutics, Inc.: overview BDTX · Nasdaq · CIK 1701541 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bdtx.md) · [Financials](/companies/bdtx/financials.md) · [Filings](/companies/bdtx/filings.md) · [Insiders](/companies/bdtx/insiders.md) Latest reported revenue: [$0](/filings/0001701541-26-000025.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001701541-26-000025). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001701541-25-000039.md) | [0.0 d](/filings/0001701541-26-000009.md) | [70.0](/filings/0001701541-26-000017.md) | [0.0](/filings/0001701541-26-000025.md) | [0.0](/filings/0001701541-25-000039.md) | [0.0 d](/filings/0001701541-26-000009.md) | [0.0](/filings/0001701541-26-000017.md) | [0.0](/filings/0001701541-26-000025.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [77.9%](/filings/0001701541-26-000017.md) | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | [80.8%](/filings/0001701541-26-000025.md) | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.28)](/filings/0001701541-25-000039.md) | not reported | [0.98](/filings/0001701541-26-000017.md) | [(0.19)](/filings/0001701541-26-000025.md) | [(0.15)](/filings/0001701541-25-000039.md) | not reported | [(0.16)](/filings/0001701541-26-000017.md) | [(0.17)](/filings/0001701541-26-000025.md) | | Free cash flow | $m | not reported | [(15.1) d](/filings/0001701541-26-000009.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0001701541-26-000009.md) | [70.0](/filings/0001701541-26-000009.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | [17.9%](/filings/0001701541-26-000009.md) | | Net margin | % | not reported | not reported | not reported | not reported | [32.0%](/filings/0001701541-26-000009.md) | | Diluted EPS | $ per share | [(3.47)](/filings/0001701541-23-000020.md) | [(2.52)](/filings/0001701541-24-000011.md) | [(1.88)](/filings/0001701541-25-000016.md) | [(1.27)](/filings/0001701541-26-000009.md) | [0.39](/filings/0001701541-26-000009.md) | | Free cash flow | $m | [(103)](/filings/0001701541-23-000020.md) | [(85.3)](/filings/0001701541-24-000011.md) | [(66.8)](/filings/0001701541-25-000016.md) | [(62.3)](/filings/0001701541-26-000009.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bdtx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $8.2m | 4,448,757 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $7.2m | 3,917,088 | | Added +2,810,248 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.9m | 2,125,270 | | Added +274,802 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $3.6m | 1,962,394 | | Added +318,647 | | [Defilade Capital Management, L.P.](/funds/2088557.md) | 2026-06-30 | $3.1m | 1,674,999 | | New +1,674,999 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $2.5m | 1,365,384 | | Added +63,720 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.3m | 1,218,171 | | Added +681,596 | | [Connor, Clark & Lunn Investment Management Ltd.](/funds/1596800.md) | 2026-06-30 | $2.0m | 1,092,885 | | Added +34,488 | | [AWM Investment Company, Inc.](/funds/1535264.md) | 2026-06-30 | $1.9m | 1,000,000 | | Added +475,000 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.7m | 896,602 | | Added +60,336 | ## Recent filings [All 481 filings](/companies/bdtx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-05 | 16:04 ET | [10-Q](/filings/0001701541-26-000025.md) | Quarterly report, period 2026-06-30 | 0001701541-26-000025 | | 2026-08-05 | 16:02 ET | [8-K](/filings/0001701541-26-000023.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001701541-26-000023 | | 2026-06-29 | 16:20 ET | [8-K](/filings/0001104659-26-078847.md) | 5.07 Shareholder vote results | 0001104659-26-078847 | | 2026-05-21 | 17:19 ET | [8-K](/filings/0001104659-26-065254.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-065254 | | 2026-05-07 | 07:20 ET | [10-Q](/filings/0001701541-26-000017.md) | Quarterly report, period 2026-03-31 | 0001701541-26-000017 | | 2026-05-07 | 07:17 ET | [8-K](/filings/0001701541-26-000015.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001701541-26-000015 | | 2026-04-29 | 16:03 ET | [DEF 14A](/filings/0001104659-26-051474.md) | Proxy statement, period 2026-06-26 | 0001104659-26-051474 | | 2026-03-16 | 16:03 ET | [10-K](/filings/0001701541-26-000009.md) | Annual report, period 2025-12-31 | 0001701541-26-000009 | | 2026-03-16 | 16:02 ET | [8-K](/filings/0001701541-26-000008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001701541-26-000008 | | 2025-12-03 | 08:20 ET | [8-K](/filings/0001104659-25-117975.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-117975 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001701541-26-000009.md), filed Mar 16, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5457e1cc-8557-4013-af18-075d44235f35) ## About the filer - CIK: 1701541 - Tickers: BDTX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.